Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR -amplified, recurrent glioblastoma: results from a multi-center, international study

导出原文传递

翻译打印收藏纠错

作者： Martin van den Bent ^[1] ; Hui K. Gan ^[2] ; Andrew B. Lassman ^[3] ; Priya Kumthekar ^[4] ; Ryan Merrell ^[5] ; Nicholas Butowski ^[6] ; Zarnie Lwin ^[7] ; Tom Mikkelsen ^[8] ; Louis B. Nabors ^[9] ; Kyriakos P. Papadopoulos ^[10] ; Marta Penas-Prado ^[11] ; John Simes ^[12] ; Helen Wheeler ^[13] ; Tobias Walbert ^[14] ; Andrew M. Scott ^[15] ; Erica Gomez ; Ho-Jin Lee ; Lisa Roberts-Rapp ; Hao Xiong ; Earle Bain ; Peter J. Ansell ; Kyle D. Holen ; David Maag ; David A. Reardon

作者单位： Medical Oncology, Royal North Shore Hospital ^[1] Brain Tumor Center, Erasmus MC Cancer Institute ^[2] Henry Ford Health System ^[3] School of Cancer Medicine, La Trobe University ^[4] AbbVie Inc. ^[5] Department of Neurological Surgery, University of California, San Francisco ^[6] NHMRC Clinical Trials Centre, University of Sydney ^[7] South Texas Accelerated Research Therapeutics (START) ^[8] Dana-Farber Cancer Institute ^[9] The University of Texas MD Anderson Cancer Center ^[10] Northwestern University ^[11] Department of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Medical ^[12] Department of Medical Oncology, School of Medicine, University of Queensland, Royal Brisbane and ^[13] University of Alabama at Birmingham ^[14] NorthShore University Health System ^[15]

关键词 ABT-414 Depatuxizumab mafodotin EGFR Antibody–drug conjugate Recurrent glioblastoma

发布时间 2018-05-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交